Additional Information

Description

Keytruda (pembrolizumab) is a humanized monoclonal antibody designed to block the interaction between the programmed death receptor-1 (PD-1) and its ligands, PD-L1 and PD-L2. By inhibiting PD-1 signaling, the drug enhances T-cell responses, allowing the immune system to recognize and attack tumor cells. It is indicated for the treatment of various cancers, including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma..

Pembrolizumab is administered as an intravenous infusion, typically given over 30 minutes every three to six weeks, depending on the indication. The recommended dosage varies based on factors such as tumor type, patient weight, and clinical response. It requires dilution before administration, and the infusion should be given under medical supervision in a healthcare setting.

Common adverse effects include fatigue, nausea, diarrhea, rash, pruritus, and decreased appetite. Immune-mediated toxicities, such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, may occur due to immune system activation. Severe reactions may require corticosteroid therapy or treatment discontinuation.